Testosterone therapy for women is prescribed at doses 10 to 20 times lower than male doses, typically delivering 0.5 to 2 mg of testosterone per day through transdermal gels, creams, or pellet implants. The goal is to restore serum levels to the mid-to-upper physiological female range (50 to 70 ng/dL) rather than to supraphysiological levels. When dosed correctly and monitored appropriately, the therapy is well-tolerated and produces measurable improvements in energy, libido, cognitive function, and muscle maintenance within 3 to 6 months.
Despite being off-label in most countries, testosterone therapy for women has more evidence behind it than most patients realize. The Global Consensus Position Statement on the Use of Testosterone Therapy for Women, published simultaneously in five major journals in 2019 and endorsed by 11 international societies, identified it as evidence-based for hypoactive sexual desire disorder in postmenopausal women. Prescribing has expanded since then. What follows is a practical guide to eligibility, formulations, dosing, and what you will actually experience during treatment.
Are You a Candidate? Eligibility Criteria Explained
Testosterone therapy is appropriate for women with documented low serum testosterone combined with at least two clinical symptoms, which typically include reduced libido, fatigue, loss of muscle tone, cognitive changes, or mood disturbance. Symptoms alone without laboratory confirmation are insufficient because symptoms of low testosterone overlap substantially with thyroid dysfunction, low ferritin, and estrogen decline. You should have a thorough workup that rules out other causes before initiating treatment.
Contraindications include active or hormone-sensitive breast cancer, pregnancy, and uncontrolled polycythemia. Women with PCOS already have elevated androgen levels in most cases and should not receive testosterone supplementation without careful workup confirming deficiency. If you have reviewed your symptoms alongside the full symptom profile for low testosterone in women, and your labs confirm the deficiency, discuss the following options with a reproductive endocrinologist or hormone specialist.
Forms of Testosterone Delivery for Women
No testosterone product is currently approved specifically for women in the United States or most of the European Union, which means all use is off-label and involves compounded formulations or male-labeled products used at fraction doses. This creates a practical challenge around consistency and quality control, which is why the delivery method and pharmacy source matter considerably.
Transdermal gel or cream is the most commonly prescribed form. A compounding pharmacy prepares a 1% testosterone cream applied to the inner wrist, upper arm, or inner thigh in doses of 0.5 to 1 gram daily, delivering approximately 5 to 10 mg of testosterone topically, of which 10% is absorbed. The effective daily dose reaching circulation is 0.5 to 1 mg. Application sites should be rotated to prevent local accumulation and should be covered or washed before skin-to-skin contact with children or male partners to prevent inadvertent transfer.
Subcutaneous pellets are inserted under the skin of the upper buttock every 3 to 6 months, releasing testosterone slowly over time. Pellets deliver consistent serum levels without the daily compliance requirement. The disadvantage is that once inserted, dosing cannot be adjusted until the pellet is exhausted, which typically takes 3 to 5 months. If side effects appear at a given dose, the only option is to wait them out.
Testosterone undecanoate injections and testosterone enanthate are used less frequently in women due to the difficulty of achieving female-range dosing with injectable preparations designed for male doses. Some practitioners use them at 12.5 to 25 mg every 4 to 6 weeks, but managing steady-state levels is harder without frequent monitoring. Skin patches designed for male use can be cut to deliver partial doses, though this is not a recommended method due to inconsistent drug release from altered surface area.
Dosing Protocol: Starting Low and Titrating to Effect
The cardinal rule of testosterone therapy in women is to start at the lowest possible effective dose and titrate slowly. The Endocrine Society recommends targeting free testosterone levels in the upper quartile of the normal female range, not the male range. A practical starting point for transdermal cream is 0.5 mg delivered testosterone per day, applied once daily. After 6 to 8 weeks, recheck free testosterone, total testosterone, and SHBG to assess where serum levels have landed. Symptom improvement follows laboratory normalization by roughly 4 to 6 weeks, so do not judge clinical response at the 6-week blood draw.
If symptoms remain and levels are below the therapeutic target, the dose can be increased to 1 mg per day. Most women find their effective dose somewhere between 0.5 and 2 mg per day of delivered testosterone. Doses above 2 mg per day risk androgenic side effects including acne, oily skin, and in some cases clitoral enlargement or voice changes. These effects are dose-dependent and largely reversible on dose reduction. They should not be ignored because they signal supratherapeutic levels that may also carry cardiovascular and hepatic risk over the long term.
You should also review how cortisol affects hormone balance during your treatment period, because chronic stress elevates cortisol, which competes with testosterone on the HPA-HPG axis and can blunt treatment response even at correct doses. Managing cortisol load is part of the clinical picture, not separate from it.
What to Expect Month by Month
The timeline for response to testosterone therapy in women is predictable enough that unrealistic expectations are one of the most common reasons women stop treatment prematurely. Here is what clinical data and practice experience suggest you will notice at each phase.
In the first 4 to 6 weeks, most women notice little change. Serum levels are still climbing toward steady state, and receptor-level changes take time to manifest as felt symptoms. Some women report a subtle improvement in energy by week 3 to 4, but the absence of dramatic early change is not a signal that the therapy is not working.
Between weeks 6 and 12, libido improvement typically becomes noticeable. This is the most testosterone-sensitive symptom in terms of timeline. Energy improvement and exercise response also begin to emerge in this window. Mood stabilization, if it occurs, usually appears around the same time. Cognitive symptoms including brain fog respond more slowly and may not be fully apparent until the 3-month mark.
At the 3 to 6 month mark, muscle composition changes become measurable. Women in resistance training programs will notice better recovery, strength gains they had lost, and improved body composition on metrics like DEXA. This is also the window where bone density improvements begin, though these take 12 to 18 months to show significantly on a DEXA scan. The metabolic improvements associated with restored androgen levels include improved insulin sensitivity, which has downstream effects on fat distribution and cardiovascular markers.
Monitoring During Testosterone Therapy
Monitoring is not optional. Women on testosterone therapy should have a full hormone panel including free testosterone, total testosterone, SHBG, estradiol, and hematocrit at 6 weeks after initiation, at 3 months, and every 6 months thereafter once stable. Hematocrit monitoring matters because testosterone stimulates erythropoiesis and elevated red blood cell count increases clotting risk. Liver function tests are relevant if using oral or injectable forms, though transdermal routes bypass first-pass metabolism and carry lower hepatic risk.
Breast cancer screening protocols should not change from age-appropriate standard care. The 2019 Global Consensus Statement found no signal of increased breast cancer risk from testosterone therapy at physiological doses, but the data beyond 3 years is limited. Women with a personal or family history of hormone-sensitive breast cancer should discuss the risk-benefit profile explicitly with an oncologist before starting.
